Exhibit 99.2
PRESS RELEASE
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
December 22, 2023 New York (N.Y.) Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology
company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th
floor, 75013 Paris, France.
At the meeting, resolutions 1 through 5 as well as resolutions 7 and 8 were adopted and resolution 6 was rejected,
consistent with the recommendations of the board of directors.
Cellectis shareholders supported the contemplated $140M additional investment by
AstraZeneca in the Company, to be effected by way of subscription of 10,000,000 newly created class A convertible preferred shares and 18,000,000 newly created class B convertible preferred shares, in each case at a price of
$5.00 per share (the Additional Investment).
The completion of the Additional Investment remains subject to the clearance of such investment
from the French Ministry of Economy pursuant to applicable foreign direct investment regulations, and other customary closing conditions.
The
Companys shareholders also approved the appointments of Mr. Marc Dunoyer and Dr. Tyrell Rivers as directors of the Cellectis board of directors, which appointment remains subject to the completion of the Additional Investment.
We are grateful to our shareholders for supporting the Additional Investment and we are looking forward to welcoming
Mr. Dunoyer and Dr. Rivers to our board of directors. Their extensive experience in the pharma industry will be an additional asset for the Company. With This Additional Investment would provide
meaningful and valued perspectives to our common ambition of bringing potentially life-saving therapies to patients with unmet medical needs said Jean Pierre Garnier, Chairman of the Board of Directors at Cellectis.
Mr. Marc Dunoyer is Chief Strategy Officer of AstraZeneca and Chief Executive Officer of Alexion, AstraZeneca Rare Disease. He had previously served as
an Executive Director and AstraZenecas Chief Financial Officer from November 2013. Mr. Marc Dunoyers career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GSK, has given him extensive
industry experience. He is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, Global Product and Portfolio Strategy from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK
and (concurrently) Chairman, GSK Japan. Mr. Dunoyer is a member of the Boards of Orchard Therapeutics Plc and JCR Pharmaceuticals. He holds an MBA from HEC Paris and a Bachelor of Law degree from Paris University.